Abstract
Chronic hepatitis C virus (HCV) infection is responsible for development of liver cirrhosis and hepatocellular carcinoma. In addition to PEGylated interferon-α, ribavirin, and HCV NS3 protease inhibitors, recently identified HCV NS5A inhibitors such as BMS-790052 showed a great promise in clinical trials as another new class of direct-acting anti-HCV therapeutics with a distinct mechanism of action. This clinical proof-of-concept study with NS5A inhibitors demonstrated that small molecules targeting a viral protein without any known enzymatic activity can also have profound antiviral effects. In conclusion, NS5A inhibitors will serve as a valuable component of future therapy for HCV patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., and Margolis, H. S., The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med., 341, 556–562 (1999).
Asselah, T., Benhamou, Y., and Marcellin, P., Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int., 29Suppl 1, 57–67 (2009).
Blight, K. J., Kolykhalov, A. A., and Rice, C. M., Efficient initiation of HCV RNA replication in cell culture. Science, 290, 1972–1974 (2000).
Fridell, R. A., Qiu, D., Wang, C., Valera, L., and Gao, M., Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother., 54, 3641–3650 (2010).
Gane, E. J., Roberts, S. K., Stedman, C. A., Angus, P. W., Ritchie, B., Elston, R., Ipe, D., Morcos, P. N., Baher, L., Najera, I., Chu, T., Lopatin, U., Berrey, M. M., Bradford, W., Laughlin, M., Shulman, N. S., and Smith, P. F., Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet, 376, 1467–1475 (2010).
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J. H., O’Boyle, D. R., 2nd, Lemm, J. A., Wang, C., Knipe, J. O., Chien, C., Colonno, R. J., Grasela, D. M., Meanwell, N. A., and Hamann, L. G., Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465, 96–100 (2010).
Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., and Rice, C. M., A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. U. S. A., 90, 10583–10587 (1993a).
Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M., and Rice, C. M., Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol., 67, 1385–1395 (1993b).
Hijikata, M., Mizushima, H., Tanji, Y., Komoda, Y., Hirowatari, Y., Akagi, T., Kato, N., Kimura, K., and Shimotohno, K., Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A., 90, 10773–10777 (1993).
Lee, C., Ma, H., Hang, J. Q., Leveque, V., Sklan, E. H., Elazar, M., Klumpp, K., and Glenn, J. S., The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology, 414, 10–18 (2011).
Lemm, J. A., O’Boyle, D., 2nd, Liu, M., Nower, P. T., Colonno, R., Deshpande, M. S., Snyder, L. B., Martin, S. W., St Laurent, D. R., Serrano-Wu, M. H., Romine, J. L., Meanwell, N. A., and Gao, M., Identification of hepatitis C virus NS5A inhibitors. J. Virol., 84, 482–491 (2010).
Liang, T. J., Rehermann, B., Seeff, L. B., and Hoofnagle, J. H., Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med., 132, 296–305 (2000).
Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., and Bartenschlager, R., Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285, 110–113 (1999).
Lok, A., Gardiner, D., Lawitz, E., Martorell, C., Everson, G., Ghalib, R., Reindollar, R., Rustgi, V., McPhee, F., Wind-Rotolo, M., Persson, A., Zhu, K., Dimitrova, D., Eley, T., Guo, T., Grasela, D., and Pasquinelli, C., Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. Hepatology (Baltimore, Md 52 (AASLD), Abstract LB-8 (2010).
Marcellin, P., Forns, X., Goeser, T., Ferenci, P., Nevens, F., Carosi, G., Drenth, J. P., Serfaty, L., De Backer, K., Van Heeswijk, R., Luo, D., Picchio, G., and Beumont, M., Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology, 140, 459–468 (2011).
Moradpour, D., Kary, P., Rice, C. M., and Blum, H. E., Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology, 28, 192–201 (1998).
Moradpour, D., Penin, F., and Rice, C. M., Replication of hepatitis C virus. Nat. Rev. Microbiol., 5, 453–463 (2007).
Neddermann, P., Quintavalle, M., Di Pietro, C., Clementi, A., Cerretani, M., Altamura, S., Bartholomew, L., and De Francesco, R., Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J. Virol., 78, 13306–13314 (2004).
Pawlotsky, J. M., The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology, 140, 746–754 (2011).
Shepard, C. W., Finelli, L., and Alter, M. J., Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 5, 558–567 (2005).
Targett-Adams, P., Graham, E. J., Middleton, J., Palmer, A., Shaw, S. M., Lavender, H., Brain, P., Tran, T. D., Jones, L. H., Wakenhut, F., Stammen, B., Pryde, D., Pickford, C., and Westby, M., Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J. Virol., 85, 6353–6368 (2011).
Tellinghuisen, T. L., Marcotrigiano, J., and Rice, C. M., Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature, 435, 374–379 (2005).
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E., O’Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., and Brunda, M. J., Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med., 343, 1666–1672 (2000).
Zeuzem, S., Asselah, T., Angus, P., Zarski, J. P., Larrey, D., Mullhaupt, B., Gane, E., Schuchmann, M., Lohse, A., Pol, S., Bronowicki, J. P., Roberts, S., Arasteh, K., Zoulim, F., Heim, M., Stern, J. O., Kukolj, G., Nehmiz, G., Haefner, C., and Boecher, W. O., Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Hepatology (Baltimore, Md 52(AASLD), Abstract LB-7 (2010).
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by Donghak Kim, Department of Biological Sciences, Konkuk University, Seoul 143-701, Korea Tel: 82-2-450-3366 E-mail: donghak@konkuk.ac.kr
Choongho Lee Assistant Professor, Microbiology Lab, Dongguk University College of Pharmacy Main Research Area Hepatitis C Virus (HCV)-induced Liver Diseases Human Papillomavirus (HPV)-induced Cervical Cancer Replication of Viral RNA or DNA Genomes Development and Mechanism of Action Study of Antiviral Drugs
Rights and permissions
About this article
Cite this article
Lee, C. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy. Arch. Pharm. Res. 34, 1403–1407 (2011). https://doi.org/10.1007/s12272-011-0921-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0921-6